Who
Neha Krishnamohan
Director
Company insider
Files Form 4 as: Director, Arcutis Biotherapeutics; Chief Financial Officer, Artiva Biotherapeutics; Chief Financial Officer, Kinnate Biopharma.
In numbers
- Trades disclosed
- 36
- Buys
- 0
- Sells
- 1
- Bought
- $0
- Sold
- $940K
- Companies
- 3
- Companies where not an officer
- 1
- First trade
- 7 Jun 2021
- Last trade
- 5 Jun 2026
- Last filed
- 9 Jun 2026
Companies traded
Activity over time
1 Nov 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 5 Jun 2026filed 9 Jun 2026 | ARQT Arcutis BiotherapeuticsBiotechnology | SEC FORM 4 Code A | —5,778 at $0.00 | filing |
| 5 Jun 2026filed 9 Jun 2026 | ARQT Arcutis Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,667 at $0.00 | filing |
| 5 Jun 2026filed 9 Jun 2026 | ARQT Arcutis Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,667 at $0.00 | filing |
| 5 Jun 2026filed 9 Jun 2026 | ARQT Arcutis BiotherapeuticsBiotechnology | SEC FORM 4 Code A | —5,778 at $0.00 | filing |
| 15 Nov 2025filed 17 Nov 2025 | ARTV Artiva BiotherapeuticsBiotechnology | SEC FORM 4 Code F | $11K3,490 at $3.25 | filing |
| 13 Nov 2025filed 17 Nov 2025 | ARQT Arcutis Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —27,052 at $0.00 | filing |
| 13 Nov 2025filed 17 Nov 2025 | ARQT Arcutis Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —12,220 at $0.00 | filing |
| 13 Nov 2025filed 17 Nov 2025 | ARQT Arcutis BiotherapeuticsBiotechnology | SEC FORM 4 Code M | $233K27,052 at $8.63 | filing |
| 13 Nov 2025filed 17 Nov 2025 | ARQT Arcutis BiotherapeuticsBiotechnology | SEC FORM 4 Code M | $92K12,220 at $7.51 | filing |
| 13 Nov 2025filed 17 Nov 2025 | ARQT Arcutis BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $911K39,272 at $23.19 | filing |
| 13 Nov 2025filed 17 Nov 2025 | ARQT Arcutis BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $29K1,232 at $23.37 | filing |
| 15 Aug 2025filed 18 Aug 2025 | ARTV Artiva BiotherapeuticsBiotechnology | SEC FORM 4 Code F | $16K5,813 at $2.75 | filing |
| 12 Jun 2025filed 16 Jun 2025 | ARQT Arcutis Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,568 at $0.00 | filing |
| 12 Jun 2025filed 16 Jun 2025 | ARQT Arcutis BiotherapeuticsBiotechnology | SEC FORM 4 Code A | —7,609 at $0.00 | filing |
| 15 May 2025filed 18 Aug 2025 | ARTV Artiva BiotherapeuticsBiotechnology | SEC FORM 4 Code F | $2,8561,341 at $2.13 | filing |
| 26 Feb 2025filed 28 Feb 2025 | ARTV Artiva BiotherapeuticsBiotechnology | SEC FORM 4 Code A | —60,000 at $0.00 | filing |
| 12 Sep 2024filed 13 Sep 2024 | ARTV Artiva BiotherapeuticsBiotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 14 Jun 2024filed 18 Jun 2024 | ARQT Arcutis Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —27,052 at $0.00 | filing |
| 14 Jun 2024filed 18 Jun 2024 | ARQT Arcutis BiotherapeuticsBiotechnology | SEC FORM 4 Code A | —10,139 at $0.00 | filing |
| 3 Apr 2024filed 5 Apr 2024 | Kinnate Biopharmaoption or derivative | SEC FORM 4 Code D | —270,000 | filing |
News
Arcutis Biotherapeutics (ARQT) Gets New Rating Uprgades from 2 Analysts; Shares ClimbARQT · insidermonkey.com · 20 Oct 2026
0 headlines in the last 90 days name Neha Krishnamohan; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.